Circulation Research, Vol 61, 539-547, Copyright © 1987 by American Heart Association

ARTICLES

Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility

RE Weishaar, DC Kobylarz-Singer, RP Steffen and HR Kaplan
Department of Pharmacology, Warner-Lambert/Parke Davis Pharmaceutical Research, Ann Arbor, Mich. 48105.

Ventricular muscle contains a low Km, cyclic AMP-specific form of phosphodiesterase (PDE III), which is believed to represent the site of action for several of new cardiotonic agents including imazodan (CI- 914), amrinone, cilostamide, and enoximone. However, species differences in the inotropic response to these agents have raised questions about the relationship between PDE III inhibition and cardiotonic activity. The present study demonstrates that these differences can be accounted for by the presence of two subclasses of PDE III in ventricular muscle and variations in the intracellular localization of these two enzymes. For these experiments, PDE III was initially isolated from canine, guinea pig, and rat left ventricular muscle. The results demonstrate that canine left ventricular muscle contains two functional subclasses of PDE III: an imazodan-sensitive form, which is membrane bound, and an imazodan-insensitive form, which is soluble. Although only weakly inhibited by imazodan, this latter enzyme is potently inhibited by the selective PDE III inhibitors, Ro 20- 1724 and rolipram. Guinea pig ventricular muscle also contains the imazodan-sensitive subclass of PDE III. Unlike canine left ventricle, however, thi enzyme is soluble in the guinea pig. No membrane-bound subclass of PDE III was observed in the guinea pig. Rat left ventricle possesses only the soluble form of PDE III, which apparently represents a mixture of the imazodan-sensitive and imazodan-insensitive subclasses of PDE III. Measurement of in vivo contractility in these three species showed that imazodan exerts a potent positive inotropic effect only in the dog, in which the imazodan-sensitive subclass of PDE III is membrane bound.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				J. Leroy, A. Abi-Gerges, V. O. Nikolaev, W. Richter, P. Lechene, J.-L. Mazet, M. Conti, R. Fischmeister, and G. Vandecasteele Spatiotemporal Dynamics of {beta}-Adrenergic cAMP Signals and L-Type Ca2+ Channel Regulation in Adult Rat Ventricular Myocytes: Role of Phosphodiesterases Circ. Res., May 9, 2008; 102(9): 1091 - 1100. [Abstract] [Full Text] [PDF]

				C. Yan, C. L. Miller, and J.-i. Abe Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart Circ. Res., March 2, 2007; 100(4): 489 - 501. [Abstract] [Full Text] [PDF]

				R. Fischmeister, L. R.V. Castro, A. Abi-Gerges, F. Rochais, J. Jurevicius, J. Leroy, and G. Vandecasteele Compartmentation of Cyclic Nucleotide Signaling in the Heart: The Role of Cyclic Nucleotide Phosphodiesterases Circ. Res., October 13, 2006; 99(8): 816 - 828. [Abstract] [Full Text] [PDF]

				D. M. Bers and M. T. Ziolo When Is cAMP Not cAMP?: Effects of Compartmentalization Circ. Res., August 31, 2001; 89(5): 373 - 375. [Full Text] [PDF]

				M. Yano, M. Kohno, T. Ohkusa, M. Mochizuki, J. Yamada, M. Kohno, T. Hisaoka, K. Ono, T. Tanigawa, S. Kobayashi, et al. Effect of milrinone on left ventricular relaxation and Ca2+ uptake function of cardiac sarcoplasmic reticulum Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1898 - H1905. [Abstract] [Full Text] [PDF]

				G.-W. He and C.-Q. Yang Vasorelaxant effect of phosphodiesterase-inhibitor milrinone in the human radial artery used as coronary bypass graft J. Thorac. Cardiovasc. Surg., May 1, 2000; 119(5): 1039 - 1045. [Abstract] [Full Text]

				J.-S. Bian, W.-M. Zhang, J.-M. Pei, and T.-M. Wong The Role of Phosphodiesterase in Mediating the Effect of Protein Kinase C on Cyclic AMP Accumulation upon kappa -Opioid Receptor Stimulation in the Rat Heart J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1065 - 1070. [Abstract] [Full Text]

				T. Tanigawa, M. Yano, M. Kohno, T. Yamamoto, T. Hisaoka, K. Ono, T. Ueyama, S. Kobayashi, Y. Hisamatsu, T. Ohkusa, et al. Mechanism of preserved positive lusitropy by cAMP-dependent drugs in heart failure Am J Physiol Heart Circ Physiol, February 1, 2000; 278(2): H313 - H320. [Abstract] [Full Text] [PDF]

				N. Sato, K. Asai, S. Okumura, G. Takagi, R. P. Shannon, Y. Fujita-Yamaguchi, Y. Ishikawa, S. F. Vatner, and D. E. Vatner Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1699 - H1705. [Abstract] [Full Text] [PDF]

				C. J. Smith, R. Huang, D. Sun, S. Ricketts, C. Hoegler, J.-Z. Ding, R. A. Moggio, and T. H. Hintze Development of Decompensated Dilated Cardiomyopathy Is Associated With Decreased Gene Expression and Activity of the Milrinone-Sensitive cAMP Phosphodiesterase PDE3A Circulation, November 4, 1997; 96(9): 3116 - 3123. [Abstract] [Full Text]

				M. Floreani, P. A. Borea, S. Gessi, L. Mosti, P. Fossa, and P. Dorigo A New Milrinone Analog: Role of Binding to A1 Adenosine Receptor in its Positive Inotropic Effect on Isolated Guinea Pig and Rat Atria J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 541 - 547. [Abstract] [Full Text]

				G. Kojda, K. Kottenberg, P. Nix, K. D. Schluter, H. M. Piper, and E. Noack Low Increase in cGMP Induced by Organic Nitrates and Nitrovasodilators Improves Contractile Response of Rat Ventricular Myocytes Circ. Res., January 1, 1996; 78(1): 91 - 101. [Abstract] [Full Text]

				Y. Shakur, K. Takeda, Y. Kenan, Z.-X. Yu, G. Rena, D. Brandt, M. D. Houslay, E. Degerman, V. J. Ferrans, and V. C. Manganiello Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3). TWO N-TERMINAL DOMAINS ARE REQUIRED FOR THE EFFICIENT TARGETING TO, AND ASSOCIATION OF, PDE3 WITH ENDOPLASMIC RETICULUM J. Biol. Chem., December 1, 2000; 275(49): 38749 - 38761. [Abstract] [Full Text] [PDF]